Moran Sean F.

SEC source: 0001193125-26-342479 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,694

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0001193125-26-057168 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,694

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0001193125-26-015427 · ownership.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,247

Underlying: Common Stock · 84,247 shares

Expires 2036-01-14

F3 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

SEC source: 0001193125-26-015427 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,395

F1 · shares: On January 14, 2026, the Reporting Person was granted 28,082 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

F2 · balance_after: This amount includes 85,714 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0001193125-25-251635 · ownership.xml · derivative · entry 3

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,386

Underlying: Common Stock · 12,981 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

SEC source: 0001193125-25-251635 · ownership.xml · nonDerivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,313

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0001193125-25-251635 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,294

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0000950170-25-022514 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,313

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0000950170-25-013702 · ownership.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,500

Underlying: Common Stock · 92,500 shares

Expires 2035-01-31

F3 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 31, 2026, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 28, 2026.

SEC source: 0000950170-25-013702 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,105

F1 · shares: On January 31, 2025, the Reporting Person was granted 27,500 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 31, 2026. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

F2 · balance_after: This amount includes 67,676 unvested RSUs subject to each grant's vesting schedule as previously reported.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 12

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,958 shares

Expires 2024-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

F6 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 8

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 7

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 11

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,217

Underlying: Common Stock · 6,730 shares

Expires 2032-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 6

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 5

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 10

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,367

Underlying: Common Stock · 7,788 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 9

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 1,567 shares

Expires 2024-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

F6 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 4

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 3

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0001209191-24-005284 · doc4.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,787 shares

Expires 2024-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-24-005284 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 unvested restricted stock units ("RSUs") that were granted on February 12, 2024, which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 12, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated, shall be forfeited upon termination of service.

SEC source: 0001209191-24-003337 · doc4.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,176

Underlying: Common Stock · 40,176 shares

Expires 2034-02-12

F2 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 12, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 12, 2025.

SEC source: 0001209191-24-003337 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,818

F1 · shares: On February 12, 2024, the Reporting Person was granted 40,176 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001.25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 12, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

SEC source: 0001209191-23-009633 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,645

Underlying: Common Stock · 934,645 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

SEC source: 0001209191-22-045137 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,272

SEC source: 0001209191-22-029031 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,272

SEC source: 0001209191-22-017781 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,272

SEC source: 0001209191-22-006505 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 538,400

Underlying: Common Stock · 538,400 shares

Expires 2032-02-01

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.

SEC source: 0001209191-21-007742 · doc4.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,300

Underlying: Common Stock · 307,300 shares

Expires 2031-02-02

F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022

SEC source: 0001209191-21-007742 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,300

Underlying: Common Stock · 307,300 shares

Expires 2031-02-02

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022.

SEC source: 0001209191-20-064849 · doc4.xml · derivative · entry 6

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2026-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F2 · derivative.exercise_date: The option is currently fully vested.

SEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 4

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,610

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

SEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 3

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 437,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-064849 · doc4.xml · derivative · entry 5

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,610

Underlying: Common Stock · 53,610 shares

Expires 2024-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F2 · derivative.exercise_date: The option is currently fully vested.

SEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,610

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

SEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-064437 · doc4.xml · derivative · entry 3

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,923

Underlying: Common Stock · 36,923 shares

Expires 2024-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F3 · derivative.exercise_date: The option is currently fully vested.

SEC source: 0001209191-20-064437 · doc4.xml · nonDerivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,610

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.35 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein

SEC source: 0001209191-20-064437 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,533

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-017383 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,000

Underlying: Common Stock · 226,000 shares

Expires 2030-03-06

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021.

SEC source: 0001209191-19-029556 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,610

SEC source: 0001209191-19-019352 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,510

SEC source: 0001209191-19-004573 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2029-01-18

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020.

SEC source: 0001209191-18-030106 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,010

SEC source: 0001209191-18-019494 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,010

SEC source: 0001209191-18-002516 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2028-01-04

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019.

SEC source: 0001209191-18-002513 · doc4.xml · derivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2028-01-04

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019.